Arovella licenses novel CAR-iNKT cell armouring technology: Media coverage
ArovellaTherapeutics Ltd is pleased to announce it has entered into a global, exclusive license with University of North Carolina Lineberger Comprehensive Cancer Center to incorporate a novel armouring cytokine technology (IL-12-TM) for its CAR-iNKT cell platform.
Media received following the announcement:
Herald Sun: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
Adelaide Now: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
Geelong Advertiser: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
Daily Telegraph: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
The Mercury: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
NT News: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform
BiotechDispatch: Arovella licences novel CARiNKT cell armouring technology